Series "matrix metalloproteinases in lung health and disease": Matrix metalloproteinases in tuberculosis

European Respiratory Journal

Volumn 38, Issue 2, 2011, Pages 456-464

  Elkington, P T ^a,b   Ugarte Gil, C A ^a,b,c   Friedland, J S ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Immunopathology; Lung; Matrix metalloproteinases; Tuberculosis

Indexed keywords

BCG VACCINE; CD14 ANTIGEN; COLLAGEN FIBRIL; DEXAMETHASONE; DOXYCYCLINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN G; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TOLL LIKE RECEPTOR;

BACTERIAL TRANSMISSION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; LUNG TUBERCULOSIS; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUBERCULOUS MENINGITIS; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; LUNG; METABOLISM; MONOCYTE; PATHOGENICITY; PATHOLOGY; RADIOGRAPHY;

EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMANS; LUNG; MATRIX METALLOPROTEINASES; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 80051510531     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00015411     Document Type: Review

References (90)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328: 856-861.
2. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med 2007; 356: 656-659.
3. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
4. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009; 136: 37-49.
5. Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb) 2006; 86: 337-348. (Pubitemid 44209336)
6. Escombe AR, Moore DA, Gilman RH, et al. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 2008; 5: e188.
7. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393-422.
8. Kim MJ, Wainwright HC, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2010; 2: 258-274.
9. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 2010; 328: 852-856.
10. Hunter RL, Jagannath C, Actor JK. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb) 2007; 87: 267-278. (Pubitemid 46951032)
11. Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003; 71: 7099-7108. (Pubitemid 37475342)
12. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med 2011; 3: 71ps6.
13. Dubos R, Dubos J. The White Plague: Tuberculosis, Man, and Society. New Brunswick/London, Rutgers University Press, 1987.
14. Davidson JM. Biochemistry and turnover of lung interstitium. Eur Respir J 1990; 3: 1048-1063.
15. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-214.
16. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61: 259-266.
17. Young D. Animal models of tuberculosis. Eur J Immunol 2009; 39: 2011-2014.
18. Chang JC, Wysocki A, Tchou-Wong KM, et al. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51: 306-311. (Pubitemid 26086477)
19. Elkington PT, Green JA, Friedland JS. Analysis of matrix metalloproteinase secretion by macrophages. Methods Mol Biol 2009; 531: 253-265.
20. Price NM, Farrar J, Tran TT, et al. Identification of a matrixdegrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 2001; 166: 4223-4230. (Pubitemid 32224957)
21. Hoheisel G, Sack U, Hui DS, et al. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb) 2001; 81: 203-209. (Pubitemid 32575228)
22. Sheen P, O'Kane CM, Chaudhary K, et al. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J 2009; 33: 134-141.
23. Park KJ, Hwang SC, Sheen SS, et al. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respiration 2005; 72: 166-175. (Pubitemid 40591530)
24. Hrabec E, Strek M, Zieba M, et al. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 2002; 6: 713-719. (Pubitemid 34832152)
25. Matsuura E, Umehara F, Hashiguchi T, et al. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sci 2000; 173: 45-52. (Pubitemid 30081775)
26. Wahl SM, Wahl LM, McCarthy JB, et al. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol 1979; 122: 2226-2231. (Pubitemid 9185781)
27. Friedland JS, Shaw TC, Price NM, et al. Differential regulation of MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis. Matrix Biol 2002; 21: 103-110. (Pubitemid 34100827)
28. Rivera-Marrero CA, Schuyler W, Roser S, et al. M. tuberculosis induction of matrix metalloproteinase-9: the role of mannose and receptor-mediated mechanisms. Am J Physiol Lung Cell Mol Physiol 2002; 282: L546-L555. (Pubitemid 34654660)
29. Elass E, Aubry L, Masson M, et al. Mycobacterial lipomannan induces matrix metalloproteinase-9 expression in human macrophagic cells through a toll-like receptor 1 (TLR1)/TLR2- and CD14-dependent mechanism. Infect Immun 2005; 73: 7064-7068. (Pubitemid 41368883)
30. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-176. (Pubitemid 10086416)
31. Quiding-Jarbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun 2001; 69: 5661-5670. (Pubitemid 32786504)
32. Elkington PT, Nuttall RK, Boyle JJ, et al.Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 2005; 172: 1596-1604. (Pubitemid 43076552)
33. Coussens A, Timms PM, Boucher BJ, et al. 1α,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology 2009; 127: 539-548.
34. Elkington PTG, Shiomi T, Breen RA, et al. Matrix metalloproteinase-1 causes tissue destruction in tuberculosis. J Clin Invest 2011; 121: 1827-1833.
35. Elkington PT, Emerson JE, Lopez-Pascua LD, et al. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J Immunol 2005; 175: 5333-5340. (Pubitemid 41456419)
36. Elkington PT, Green JA, Emerson JE, et al. Synergistic upregulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am J Respir Cell Mol Biol 2007; 37: 431-437. (Pubitemid 47502718)
37. Price NM, Gilman RH, Uddin J, et al. Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks. J Immunol 2003; 171: 5579-5586. (Pubitemid 37432849)
38. Zhu XW, Price NM, Gilman RH, et al. Multinucleate giant cells release functionally unopposed matrix metalloproteinase-9 in vitro and in vivo. J Infect Dis 2007; 196: 1076-1079. (Pubitemid 47580303)
39. Green JA, Elkington PT, Pennington CJ, et al. Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-κB- and activator protein-1-dependent monocyte networks. J Immunol 2010; 184: 6492-6503.
40. Gupta RK, Haris M, Husain N, et al. DTI derived indices correlate with immunohistochemistry obtained matrix metalloproteinase (MMP-9) expression in cellular fraction of brain tuberculoma. J Neurol Sci 2008; 275: 78-85.
41. Harris JE, Nuttall RK, Elkington PT, et al. Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression and secretion in central nervous system tuberculosis in vitro and in vivo. J Immunol 2007; 178: 1199-1207. (Pubitemid 46095194)
42. Kuo HP, Wang YM, Wang CH, et al. Matrix metalloproteinase-1 polymorphism in Taiwanese patients with endobronchial tuberculosis. Tuberculosis (Edinb) 2008; 88: 262-267.
43. Ganachari M, Ruiz-Morales JA, Gomez de la Torre Pretell JC, et al. Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals. PLoS One 2010; 5: e8881.
44. Wang CH, Lin HC, Lin SM, et al. MMP-1(-1607G) polymorphism as a risk factor for fibrosis after pulmonary tuberculosis in Taiwan. Int J Tuberc Lung Dis 2010; 14: 627-634.
45. Lee SH, Han SK, Shim YS, et al. Effect of matrix metalloproteinase-9- 1562C/T gene polymorphism on manifestations of pulmonary tuberculosis. Tuberculosis (Edinb) 2009; 89: 68-70.
46. Taylor JL, Hattle JM, Dreitz SA, et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 2006; 74: 6135-6144. (Pubitemid 44657392)
47. Rivera-Marrero CA, Schuyler W, Roser S, et al. Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of Mycobacterium tuberculosis. Microb Pathog 2000; 29: 231-244.
48. Izzo AA, Izzo LS, Kasimos J, et al. A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection. Tuberculosis (Edinb) 2004; 84: 387-396. (Pubitemid 39451905)
49. Hernandez-Pando R, Orozco H, Arriaga K, et al. Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice. Int J Exp Pathol 2000; 81: 199-209. (Pubitemid 30485819)
50. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol 2004; 22: 599-623. (Pubitemid 38680435)
51. Nuttall RK, Sampieri CL, Pennington CJ, et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-134. (Pubitemid 38471586)
52. Balbin M, Fueyo A, Knauper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001; 276: 10253-10262.
53. Leber TM, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 1997; 249: 24-28. (Pubitemid 27251938)
54. Volkman HE, Pozos TC, Zheng J, et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010; 327: 466-469.
55. Thuong NT, Dunstan SJ, Chau TT, et al. Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog 2008; 4: e1000229.
56. Volpe E, Cappelli G, Grassi M, et al. Gene expression profiling of human macrophages at late time of infection with Mycobacterium tuberculosis. Immunology 2006; 118: 449-460. (Pubitemid 44079565)
57. Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 2010; 5: e12266.
58. Russell DG, VanderVen BC, Lee W, et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 2010; 8: 68-76.
59. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
60. van der Sar AM, Spaink HP, Zakrzewska A, et al. Specificity of the zebrafish host transcriptome response to acute and chronic mycobacterial infection and the role of innate and adaptive immune components. Mol Immunol 2009; 46: 2317-2332.
61. Cury JD, Campbell EJ, Lazarus CJ, et al. Selective up-regulation of human alveolar macrophage collagenase production by lipopolysaccharide and comparison to collagenase production by fibroblasts. J Immunol 1988; 141: 4306-4312. (Pubitemid 19018221)
62. O'Kane CM, Elkington PT, Friedland JS. Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur J Immunol 2008; 38: 1321-1330.
63. O'Kane CM, Elkington PT, Jones MD, et al. STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis. Am J Respir Cell Mol Biol 2010; 43: 465-474.
64. Harris JE, Fernandez-Vilaseca M, Elkington PT, et al. IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J 2007; 21: 356-365. (Pubitemid 46213483)
65. Agarwal N, Bishai WR. Subversion from the sidelines. Science 2010; 327: 417-418.
66. Rand L, Green JA, Saraiva L, et al. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade. J Immunol 2009; 182: 5865-5872.
67. Harris JE, Green JA, Elkington PT, et al. Monocytes infected with Mycobacterium tuberculosis regulate MAP kinase-dependent astrocyte MMP-9 secretion. J Leukoc Biol 2007; 81: 548-556. (Pubitemid 46198407)
68. Lehman J. para-Aminosalicylic acid in the treatment of tuberculosis. Lancet 1946; i: 15-16.
69. Agarwal N, Lamichhane G, Gupta R, et al. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 2009; 460: 98-102.
70. Basu S, Pathak S, Pathak SK, et al. Mycobacterium avium-induced matrix metalloproteinase-9 expression occurs in a cyclooxygenase-2- dependent manner and involves phosphorylation- and acetylationdependent chromatin modification. Cell Microbiol 2007; 9: 2804-2816. (Pubitemid 350066566)
71. Clark IM, Swingler TE, Sampieri CL, et al. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378.
72. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-1286. (Pubitemid 35430589)
73. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
74. Green JA, Tran CT, Farrar JJ, et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. PLoS One 2009; 4: e7277.
75. Simmons CP, Thwaites GE, Quyen NT, et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 2005; 175: 579-590. (Pubitemid 40884364)
76. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
77. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667-676.
78. Behar SM, Divangahi M, Remold HG. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 2010; 8: 668-674.
79. Gapski R, Hasturk H, Van Dyke TE, et al. Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial. J Clin Periodontol 2009; 36: 149-156.
80. Lindeman JH, Abdul-Hussien H, van Bockel JH, et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119: 2209-2216.
81. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31: 325-342. (Pubitemid 30100042)
82. Hanemaaijer R, Sorsa T, Konttinen YT, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumour necrosis factor-alpha and doxycycline. J Biol Chem 1997; 272: 31504-31509. (Pubitemid 28013291)
83. Smith GN Jr, Yu LP Jr, Brandt KD, et al. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998; 25: 532-535. (Pubitemid 28109358)
84. Shlopov BV, Smith GN Jr, Cole AA, et al. Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999; 42: 719-727. (Pubitemid 29171992)
85. Alvarez JI, Krishnamurthy J, Teale JM. Doxycycline treatment decreases morbidity and mortality of murine neurocysticercosis: evidence for reduction of apoptosis and matrix metalloproteinase activity. Am J Pathol 2009; 175: 685-695.
86. Meli DN, Coimbra RS, Erhart DG, et al. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun 2006; 74: 3890-3896. (Pubitemid 43993320)
87. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003; 47: 3630-3633. (Pubitemid 37345735)
88. Hemmings FJ, Farhan M, Rowland J, et al. Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 537-543.
89. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392. (Pubitemid 34270240)
90. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010; 33: 567-577.